Serum Lectin-Like Oxidized-Low Density Lipoprotein Receptor-1 and Adiponectin Levels Are Associated With Coronary Artery Disease Accompanied With Metabolic Syndrome

Abstract

Background:Coronary artery disease (CAD) is a major public health problem for developed and developing countries and is the single leading cause of death worldwide.Objectives:There is very few evidence regarding changes of both serum Lectin-like oxidized-low density lipoprotein receptor-1 (LOX-1) and adiponectin in patients with CAD accompanied with metabolic syndrome (MS). Here we aimed to evaluate serum levels of LOX-1 and adiponectin in patients with CAD accompanied with MS.Patients and Methods:Thirty patients with coronary artery disease without metabolic syndrome, 30 patients with coronary artery disease and metabolic syndrome, 30 ones with metabolic syndrome and 30 healthy subjects were enrolled. For all subjects, a questionnaire was filled to collect data, and peripheral blood samples were collected aseptically from the antecubital vein to measure serum Lectin-like oxidized-low density lipoprotein receptor-1 and adiponectin levels by enzyme-linked immunosorbent assay.Results:Serum LOX-1 level was highest in CAD + MS group; the difference between control and disease groups was statistically significant (P < 0.001). Adiponectin level had the lowest value in CAD + MS group; the difference between control and disease groups was statistically significant (P < 0.05). No significant differences were observed in serum Lectin-like oxidized-low density lipoprotein receptor-1and adiponectin in patients with different ages and gender. Serum LOX-1 level was changed negatively and linearly (R2 = 0.721) correlated with adiponectin level in different groups.Conclusions:Patient with CAD and MS had higher risk than those with only CAD because of lipid and glucose metabolism abnormalities. Combination measurements of serum LOX-1 and adiponectin levels may be helpful to evaluate the severity of CAD together with MS.

Serum Levels of Carbamylated LDL and Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Are Associated with Coronary Artery Disease in Patients with Metabolic Syndrome

“…In contrast to them, we wanted to elucidate the role of LOX-1 in the development of MetS, but, on the other hand, we also tried to evaluate the risk of CAD development on the background of existing MetS. Our observation that the concentration of sLOX-1 increased gradually from controls through MetS patients, being the highest in the MetS + CAD subgroup, is in concordance with a clinical study conducted by Sayed et al [36]. Furthermore, our subsequent ROC analysis outlined that sLOX-1 was also able to detect CAD in MetS subjects.…”

Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 acts as a new biomarker for NSTEMI and STEMI patients

“…The LOX-1concen-directly associated with negative impact on cardiovascular and cerebrovascular events (MACCEs), perhaps sLOX-1 considered as a diagnostic and prognostic biomarker 22 . Circulating soluble LOX-1 expressions noticeably increased in patients with angina pectoris and closely linked with proximal and middle segments of the left anterior descending coronary artery lesions (LAD), moreover, in our previous research, we also demonstrated serum LOX-1 levels had significantly higher in stable coronary artery disease and metabolic syndrome patients than healthy subjects 10,8 . It has been recognized that circulating LOX-1 concentrations were obviously up-regulated in dyslipidemic, hypertensive, diabetes and metabolic syndrome patients 17 .…”

“…They suggested elevated circulating LOX-1 concentrations might be used as a helpful biomarker for higher risk of stable coronary artery plaque rupture patients 15 . In our previous study, we found the serum levels of LOX-1 were significantly increased in stable coronary artery disease patients and strong association with metabolic syndrome 8 . Circulating sLOX-1 was markedly elevated in acute coronary syndrome (ACS) patients as compared with non-ACS patient, considered as a reliable specific marker for the recognition of ACS patients 11,16 .…”

“…Intimal smooth muscle cells and lipid-laden macrophages are the major sources of LOX-1 expression. Furthermore, LOX-1 is also released by cardiomyocytes, fibroblasts, adipocytes, platelets, neurons, lungs and the placenta 7,8 . Soluble LOX-1 has usually been detected in serum and plasma, and sLOX-1concentrations have been directly illustrated of the LOX-1 expression 9 .…”